The European Medicines Agency says the pilot EU project on drug safety signal detection is being extended again because “more robust data” are needed before the project is rolled out to all manufacturing authorization holders. A relatively low number of signals have been notified under the pilot to date, and only one of these was considered worthy of evaluation.
Manufacturers of the 300-odd substances involved have been told to carry on monitoring them for the duration of the pilot, which is now
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?